Campath, Vidaza Payments Raised In OPPS Rule; Zevalin, Bexxar Unchanged
Executive Summary
Ilex' Campath (alemtuzumab) will receive enhanced reimbursement in the hospital outpatient setting under the final 2005 OPPS rule
You may also be interested in...
Pharmion Vidaza Clears FDA With Full Approval For Bone Marrow Disorder
Pharmion plans to launch Vidaza for the treatment of myelodysplastic syndromes in July, following FDA approval May 19
Genzyme Enters Oncology Market Via $1 Bil. Acquisition Of Ilex
Genzyme will pay $1 bil. for its first marketed oncology therapeutic agent through the acquisition of Ilex Oncology
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011